Jazz Pharmaceuticals plc JAZZ announced that the European Commission approved its new sleep drug, Sunosi (solriamfetol). The drug will be available in Europe as a treatment to improve wakefulness and ...

DUBLIN, March 20, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Sunosi™ (solriamfetol) to improve wakefulness ...

Axsome Therapeutics, Inc. AXSM announced that it has entered into a definitive agreement with Jazz Pharmaceuticals JAZZ to acquire the latter’s new sleep drug, Sunosi (solriamfetol). The drug is ...

The Drug Enforcement Agency (DEA) has designated Sunosi (solriamfetol; Jazz Pharmaceuticals) a Schedule IV controlled substance. The Drug Enforcement Agency (DEA) has designated Sunosi (solriamfetol; ...

Jazz Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved Sunosi (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with ...

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the United ...

Jazz Pharmaceuticals has had an FDA approval in hand for sleepiness med Sunosi for months, but now it can start planning its official rollout. On Monday, the Drug Enforcement Agency tagged the drug ...

Jazz Pharmaceuticals started prepping the ground last year for its new sleep drug launch, and now it's official: The biopharma's Sunosi is rolling out this week with branded doctor advertising, a ...

(RTTNews) - The FDA has approved Jazz Pharmaceuticals plc's (JAZZ) once-daily Sunosi for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Sunosi in doses of 75 mg ...